The tests are made for those markets where the government or regulatory bodies prefer a multi-target coronavirus diagnostic. Credit: Bokskapet from Pixabay.

Co-Diagnostics’ Indian joint venture, CoSara Diagnostics, has received clearance from the Central Drugs Standard Control Organisation (CDSCO) for its Covid-19 test, Saragene COVID-19 2-gene multiplex RT-PCR test.

The latest development will allow CoSara to manufacture and sell its test as an in vitro diagnostic (IVD) for the qualitative detection of the SARS-CoV-2 virus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Saragene test kit, based on a test originally designed by the company, utilises Co-Diagnostics’ CoPrimer technology.

In February, Co-Diagnostics secured the regulatory CE Mark approval for its Logix Smart SARS-CoV-2 (genes RdRp / E) multiplex test.

To identify the virus presence, both the tests target two gene markers of the SARS-CoV-2 genome, RdRp and E-gene.

Co-Diagnostics CEO Dwight Egan said: “Tests built on our CoPrimer technology have several advantages over other platforms, including the enhanced multiplex capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe that the highly specific nature of the new Saragene test which follows World Health Organization guidance will help CoSara be able to play an even more active role in the battle against this pandemic.”

The tests are for those markets where the government or regulatory bodies prefer a multi-target coronavirus diagnostic.

CoSara Director Mohal Sarabhai said: “Our honourable Prime Minister Shri Narendra Modi has endorsed the hike in number of available RT-PCR tests to keep the Covid-19 positivity rate under 5%.

“With this clearance in place, CoSara is geared up for this challenge by providing affordable, high quality, ‘Made in India’ 2-gene multiplex COVID-19 RT-PCR tests across the country.”

Earlier, CoSara obtained CDSCO clearance for RT-PCR tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) to be manufactured and sold as IVDs in India.